Risk stratification, active surveillance, surgery, radiation, ADT & intensification, advanced disease, genomic testing, clinical trials, supportive care, and practical resources — organized by where you are in the journey.
This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature, NCCN Prostate Cancer Guidelines v5.2026, AUA/ASTRO/SUO guidelines, EAU guidelines, and clinical trial records. Every important decision must be made together with the patient’s medical team — urologists, radiation oncologists, medical oncologists, pathologists, and primary care doctors. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. Trouvera’s guides are produced using AI-assisted research synthesis with human editorial review; it is not written by treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. Every option discussed in this guide is intended as an addition to, not a replacement for, the evidence-based standard treatments delivered by a qualified medical team. The foundation of prostate cancer care is accurate risk stratification, complete staging, guideline-directed treatment matched to risk group, and integrated supportive care. Genomic testing, clinical trials, PSMA-targeted approaches, and supportive measures are all added on top of standard care — never instead of it.
Safety warning. Never change, stop, or start cancer treatment without your medical team’s knowledge. Do not replace proven treatment with unproven alternatives. Contact your medical team promptly for new leg weakness or numbness, difficulty controlling the bladder or bowels, severe or sudden bone pain, inability to urinate, or fever above 100.4°F during chemotherapy — these can require urgent attention.
Content last reviewed: May 2026 · Based on NCCN Prostate Cancer v5.2026, AUA/ASTRO/SUO, EAU guidelines, and landmark trials (ProtecT, CHAARTED, STAMPEDE, LATITUDE, ARASENS, PEACE-1, VISION, EMBARK, and others) · Always verify with your medical team.
⚡ Quick Start — If You Read Nothing Else
The 8 most important things to know right now.
Most prostate cancers grow slowly. Many men live long, full lives with prostate cancer — it is rarely an emergency requiring immediate action.
Active surveillance is a valid choice for low-risk disease. Monitoring instead of treating avoids side effects while keeping cure rates high if things change.
Your Gleason/ISUP grade matters most. The grade group (1”“5) tells you how aggressive the cancer is far better than PSA alone.
Get a second pathology opinion. Gleason grading is subjective — an expert review at a high-volume center can change your grade and your treatment plan.
Understand your risk group. Low, intermediate, or high risk determines the right treatment approach — there is no one-size-fits-all answer.
PSA alone doesn't tell the whole story. PSA levels can be elevated for many reasons; trends over time and other factors matter more than a single number.
Treatment side effects are manageable. Urinary and sexual side effects from surgery or radiation are real, but modern techniques and rehab programs help most men recover.
Don't rush the decision. You almost always have weeks to research, get opinions, and choose — taking time leads to better outcomes and fewer regrets.
▼ Collapse
Understanding Prostate Cancer
The prostate is a small, walnut-sized gland that sits below the bladder and in front of the rectum. It produces fluid that nourishes and carries sperm. Prostate cancer begins when cells in this gland grow out of control. Most prostate cancers are adenocarcinomas — arising from the gland cells that make prostate fluid.
Prostate cancer is unusual among cancers in how wide its spectrum is. Some forms grow so slowly that a man may live his whole life without needing treatment. Others are aggressive and can spread to lymph nodes, bones, and other organs. Two men both told “you have prostate cancer” may have diseases that behave completely differently.
Key message. Prostate cancer is not one disease — it is a spectrum. Getting the diagnosis right, with accurate risk stratification, is the single most important first step, because it determines everything that follows.
In the United States, the American Cancer Society estimates roughly 333,830 new cases and about 36,320 deaths in 2026. About 1 in 8 men will be diagnosed in his lifetime. It is the most common non-skin cancer in American men and the second leading cause of cancer death in men. The average age at diagnosis is about 67.
The five-year relative survival rate is about 99% for localized or regional disease and about 38% for distant metastatic disease. Two important cautions apply: first, these averages mix the 85-year-old with several other illnesses and the fit 58-year-old. Second, they are backward-looking — today’s treatments are better than those that produced today’s survival numbers, so a man diagnosed now likely has a better realistic outlook than historical figures suggest, especially for advanced disease.
Age. The strongest risk factor. Risk rises sharply after 50; most diagnoses occur after 65.
Family history. A father or brother with prostate cancer roughly doubles risk. A family history of breast, ovarian, or pancreatic cancer — especially with BRCA1/2 mutations — also raises risk.
Race and ethnicity. Black men have the highest incidence and roughly twice the mortality of White men, and often present younger with more aggressive disease. This reflects a mix of biology and disparities in screening and access.
Inherited gene mutations. BRCA2, BRCA1, ATM, CHEK2, HOXB13, and Lynch syndrome genes increase risk and can influence treatment. About 10% of prostate cancers have a hereditary component.
Lifestyle and environment. Obesity, smoking, and a Western diet are associated with modestly higher risk and worse outcomes. Certain exposures (e.g., Agent Orange) have been linked to higher risk.
Three big factors explain most of the difference in outcomes:
Risk group and stage at diagnosis. Low-risk localized disease has near-100% long-term survival with modern care. Metastatic disease is more serious, but has seen major survival gains in the past decade.
Tumor biology and genomics. Some tumors carry DNA-repair defects (BRCA2 and other HRR mutations) that make them more aggressive but also more responsive to specific drugs. MSI-high status opens immunotherapy. Accurate molecular profiling changes the menu of options.
Quality and timeliness of care. Experienced, high-volume surgeons and radiation oncologists, multidisciplinary teams, accurate staging, and access to trials all move outcomes. This is one of the few factors a family can directly influence.
The first few weeks are among the most important — and also when families have the least information and the most fear. A few grounding points:
The clock is usually measured in weeks, not hours. For localized disease there is almost always time to gather information, get second opinions, and make a thoughtful decision. For high-risk or metastatic disease the pace quickens, but there is still usually time to do the key homework.
Two things matter most in this window. First, make sure the diagnosis and risk stratification are accurate and complete. Second, understand the standard-of-care options for the patient’s specific risk group before considering anything else.
A warning that applies throughout this guide. Standard, guideline-directed treatment is the floor of every good plan. Genomic testing, clinical trials, PSMA-targeted approaches, and supportive measures are all added on top of standard care — never instead of it. Delaying or weakening proven treatment to pursue unproven supplements, diets, or “alternative” protocols is one of the most damaging mistakes a family can make.
Early Detection & Screening
Unlike some cancers, prostate cancer does have a screening tool — the PSA blood test — and early detection meaningfully improves outcomes. However, screening involves trade-offs that are important to understand.
Prostate-specific antigen (PSA) is a protein made by prostate cells — both normal and cancerous. An elevated PSA prompts further investigation, but PSA alone cannot diagnose cancer. PSA can also rise from benign prostate enlargement (BPH), inflammation, recent ejaculation, or vigorous cycling. Some medications (finasteride, dutasteride) lower PSA.
Two derived measures help interpret PSA: PSA density (PSA relative to prostate size — a density below about 0.15 ng/mL/g is reassuring) and PSA doubling time (how fast PSA rises — a shorter doubling time signals more aggressive biology).
What the guidelines say (USPSTF 2018): for men aged 55–69, PSA screening is an individual choice made after discussing the benefits and harms with a clinician (grade C). Routine PSA screening is not recommended for men aged 70 and older (grade D), because the harms of over-detection outweigh the benefit at that age. Higher-risk men (Black men, BRCA/HRR carriers, strong family history) generally start the conversation earlier (around age 40–45 per AUA).
Screening recommendations involve shared decision-making between a man and his doctor, weighing the benefits of early detection against the risks of overdiagnosis. General guidance:
Average-risk men: Discuss PSA screening starting around age 50, with shared decision-making about its benefits and limits.
Higher-risk men — those with a strong family history, Black men, and men who carry a known inherited mutation such as BRCA2 — should generally talk with their doctor about starting PSA-based screening earlier, commonly around age 40 to 45.
Modern MRI has transformed the screening pathway. Multiparametric MRI (mpMRI) before biopsy helps target suspicious areas and can reduce unnecessary biopsies.
A prostate cancer diagnosis in the family is not a reason for relatives to panic, but it is a reason to pay attention. If the patient has metastatic, high-risk, very-high-risk, or node-positive disease, or if an inherited mutation is found, relatives can pursue “cascade testing” (testing family members for that specific mutation) through a genetic counselor.
The key step: If a patient is found to carry an inherited mutation (BRCA2, BRCA1, ATM, CHEK2, or others), first-degree relatives should be offered cascade genetic testing. A relative who tests positive can then be enrolled in earlier, more intensive screening.
Risk Stratification: Why It Drives Every Decision
Doctors describe prostate cancer using three core pieces of information — Grade Group, PSA, and stage. Together they define the risk group, and the risk group drives nearly every treatment recommendation. Understanding this framework is the single most useful thing a family can do early.
When PSA trends or imaging raise suspicion, a prostate biopsy is performed — typically 12 or more tissue cores. A pathologist grades how abnormal the cells look. Modern practice uses the Grade Group system (1 through 5):
Grade Group
Gleason Score
What It Means
Grade Group 1
3+3 = 6
Lowest risk. Cells look only mildly abnormal. Often very slow-growing. Frequently suitable for active surveillance.
Grade Group 2
3+4 = 7
Favorable intermediate risk. Mostly slow-growing pattern, with a minority of more aggressive pattern.
Grade Group 3
4+3 = 7
Unfavorable intermediate risk. The tumor is mostly the more aggressive pattern.
Grade Group 4
8 (4+4, 3+5, 5+3)
High risk. Aggressive disease that usually requires definitive, often multimodal, treatment.
Grade Group 5
9–10
Very high risk. Highly aggressive, with significant risk of microscopic spread.
T (tumor): T1 — not felt or seen on imaging. T2 — confined to the prostate. T3 — extends through the capsule (T3a) or into the seminal vesicles (T3b). T4 — invades nearby structures.
N (nodes): N1 means regional pelvic lymph nodes are involved.
M (metastasis): M1 means distant spread — M1a non-regional lymph nodes, M1b bone, M1c other organs.
The NCCN combines Grade Group, PSA, and stage to place newly diagnosed localized cancer into risk groups. A notable change in the 2026 guidelines: the panel eliminated the separate “very-low-risk” category, merging it into “low risk,” because management is the same and simplifying the label reduces anxiety and overtreatment.
Risk Group
Typical Features
Usual Approach
Low
Grade Group 1, PSA < 10, confined to prostate
Active surveillance preferred for most
Favorable intermediate
Grade Group 1 or 2 with a single intermediate-risk factor, < 50% positive cores
Active surveillance for selected men, or surgery / radiation
Unfavorable intermediate
Grade Group 3, or Grade Group 2 with two or more intermediate-risk factors
Definitive treatment usually recommended (surgery, or radiation ± short-term ADT)
High
Grade Group 4–5, or PSA > 20, or cT3a
Multimodal therapy: surgery + node dissection, or radiation + long-term ADT
Very high
cT3b–cT4, primary Gleason pattern 5, or multiple high-risk features
Radiation + long-term ADT ± intensification, or surgery + adjuvant therapy
Metastatic (M1)
Distant spread to nodes, bone, or organs
Systemic therapy backbone (ADT + intensification); local therapy in selected cases
Important. These tables are a starting point, not a rigid rule. Age, life expectancy, other health conditions, baseline urinary and sexual function, and the patient’s own priorities all modify the choice. The right plan is the one that matches both the biology of the cancer and the values of the man being treated.
NCCN guidelines recognize tissue-based genomic classifiers — including the Decipher test and the multimodal AI test ArteraAI Prostate — across the risk groups. In low-risk disease a high genomic score can support more intensive active surveillance. In intermediate- and high-risk disease they help refine decisions about whether and how long to add hormone therapy, and after surgery they help weigh additional radiation. These tools support shared decisions; they do not override Grade Group, PSA, and stage. See the Genomic Testing section for detail.
The Diagnostic & Decision-Making Window
The weeks right after diagnosis are when several decisions can still be made that, if missed, close off options later. This section covers the concrete work that should happen — imaging, genomic testing, second-opinion pathology, and a checklist.
Multiparametric MRI (mpMRI) produces detailed images of the prostate and assigns a PI-RADS score (1–5) to suspicious areas. It is now standard before biopsy in many settings — helping target biopsies, reduce unnecessary procedures, and guide active surveillance.
PSMA PET imaging is a nuclear-medicine scan using a tracer that binds to a protein on prostate cancer cells. It detects disease with higher sensitivity than conventional CT and bone scan, including small nodal or bone deposits those scans miss. NCCN and other guidelines support PSMA PET for initial staging of unfavorable-intermediate, high, and very-high-risk disease, and for biochemical recurrence. It frequently changes management.
One honest caveat: when PSMA PET finds very small-volume disease that conventional imaging cannot see, the optimal treatment approach is still being refined. Interpretation requires experience, as benign uptake can mimic cancer.
Having the biopsy slides reviewed by a specialized genitourinary pathologist at an academic center is one of the highest-value, lowest-cost steps a family can take. Expert re-review can change the Grade Group or risk group in a meaningful share of cases — and the risk group drives the entire treatment plan. This can usually be arranged remotely without travel.
☐ PSA history documented — all values with dates; PSA density noted if available
☐ mpMRI obtained and reviewed
☐ Biopsy report confirmed — includes Grade Group, number of positive cores, percent cancer per core
☐ NCCN risk group assigned (Low through Very High, or Regional / Metastatic)
☐ Staging imaging if unfavorable-intermediate-risk or higher — PSMA PET, or CT + bone scan
☐ Second-opinion pathology review of biopsy slides at an academic center
☐ Genomic classifier (e.g., Decipher or ArteraAI) discussed where it would change a decision
☐ Germline genetic testing ordered if metastatic, high/very-high risk, node-positive, or strong family history
☐ Somatic tumor testing ordered if metastatic disease
☐ Life-expectancy and other-health-conditions assessment completed
☐ Consultations scheduled — urology AND radiation oncology (add medical oncology if high-risk or metastatic)
Practical timing tip. Genomic results typically take 2–4 weeks. Do not delay starting standard therapy while waiting — unless enrollment in a specific clinical trial depends on a result. For metastatic disease, start the ADT backbone promptly; genomic results refine what is added, not whether to begin.
Collect records: the complete PSA history with dates; the biopsy pathology report with Grade Group, number of positive cores, and percent cancer per core; all imaging reports and discs; a current medication and allergy list.
Write down the family history: any prostate, breast, ovarian, pancreatic, or colorectal cancer in relatives, with ages at diagnosis.
Keep a symptom log: urinary symptoms, any bone pain, fatigue, weight changes — with severity and effect on daily life.
Bring a second person to take notes and, with permission, record the conversation.
Keep a binder. PSA history with dates, the biopsy report with Grade Group, all imaging discs and reports, any second-opinion pathology reports, genomic test results, and a current medication list. Bring it to every visit.
Evaluating Treatment Claims
Families searching online will encounter long lists of additional therapies — repurposed drugs, high-dose supplements, special diets, metabolic protocols. Understanding how to sort genuine options from noise helps protect the patient.
Where does the evidence come from? Peer-reviewed journals (PubMed: pubmed.ncbi.nlm.nih.gov) are the strongest source. Be especially wary of any website that sells the product it recommends.
Has it been tested in prostate cancer specifically, and in people? Laboratory studies in dishes are a very early step.
What kind of human study? A randomized trial is the gold standard. A case report — one patient who did well — tells you almost nothing.
Does it interfere with standard treatment? Even a safe-seeming supplement can change how the liver processes cancer drugs or raise bleeding risk before surgery.
Does anyone with no financial stake recommend it? If the only promoters are the sellers, treat that as a serious warning sign.
Are the doctors at major prostate cancer centers using it? If the specialists at Huntsman, Johns Hopkins, MD Anderson, and similar centers are not using a treatment, there is usually a reason.
A warning worth stating directly. If anyone — a practitioner, a website, a well-meaning acquaintance — tells you that standard treatment is poison or a fraud and that some natural protocol can replace it, that person should not be guiding cancer decisions. Standard care is imperfect, and this guide is honest about that. But it has, by an enormous margin, the strongest evidence. Build on it. Add to it carefully, with the team’s knowledge. Do not abandon it.
Active Surveillance: When It Is Right and What It Requires
Active surveillance is active treatment, not “doing nothing.” It is a structured monitoring program designed to catch any progression early enough to still cure the cancer, while sparing or delaying urinary, sexual, and bowel side effects for men whose cancer is unlikely to threaten them.
Under current NCCN guidance, active surveillance is the preferred approach for low-risk disease and a reasonable option for favorable intermediate-risk disease (particularly in older men or those with other significant health conditions). Typical criteria:
Grade Group 1 (Gleason 6) — or selected Grade Group 2 with low volume
PSA usually below 10–15 ng/mL
Clinical stage T1–T2a
Limited biopsy involvement (often fewer than 3 positive cores, under 50% cancer per core) and low PSA density
Life expectancy matters: men with a life expectancy under about 10 years are generally managed with watchful waiting — a less intensive approach that treats symptoms if they arise — rather than active surveillance.
Component
Typical Frequency
PSA blood test
Every 3–6 months; may extend to every 6–12 months if stable
Digital rectal exam
Every 6–12 months
Multiparametric MRI
At baseline; repeated every 1–2 years, or sooner if PSA rises
Confirmatory biopsy
Within 6–12 months of diagnosis; then every 1–3 years
Genomic classifier
Optional; consider in borderline or favorable-intermediate cases
Grade Group rises on repeat biopsy (especially to Grade Group 3 or higher)
More cores positive, or a greater percentage of cancer per core
A significant or rapid PSA rise (a short PSA doubling time)
A new or enlarging lesion on MRI (PI-RADS 4–5)
The patient’s own preference — some men find living with an untreated cancer too stressful, and that is a legitimate reason to treat
Doing surveillance well. Active surveillance only works if it is actually done. Missing scheduled PSA tests or biopsies defeats the purpose. Choose a team experienced in surveillance, ask for their exact written protocol and their specific triggers for switching to treatment, and put every appointment on the calendar.
Radical Prostatectomy
Radical prostatectomy removes the entire prostate gland and the seminal vesicles, and — for intermediate- and high-risk disease — often pelvic lymph nodes. It is a proven curative option for localized disease, generally offered to men with a life expectancy of about 10 years or more who are good surgical candidates.
Approach
Key Features
Robot-assisted (RARP)
Minimally invasive, magnified 3-D vision, small incisions. Now the most common approach in the U.S. Generally faster recovery; cancer-control outcomes at least comparable to open surgery.
Open (retropubic or perineal)
The traditional approach, with a long track record of oncologic outcomes.
Laparoscopic
Minimally invasive without robotic assistance; requires substantial surgeon expertise.
For most men, oncologic outcomes are similar between an experienced robotic surgeon and an experienced open surgeon. The key variable is the surgeon’s experience and volume, not the tool.
Nerve-sparing means preserving the cavernous nerves that run alongside the prostate and control erections. Sparing nerves on both sides gives the best chance of recovering erectile function — but it may not be oncologically safe if the cancer is extensive or close to those nerves. Techniques such as Retzius-sparing surgery may speed early continence recovery. Whether nerve-sparing is appropriate depends on the MRI, the biopsy map, and the risk group.
This matters as much as the choice of surgery itself. Multiple studies show that higher surgeon and hospital volumes are associated with better cancer-control and functional outcomes — fewer positive margins, better continence, better potency recovery. This is not about prestige; it is about technical repetition and an experienced team. Always ask about annual case volume.
Urinary continence: most men have some leakage at first. Recovery continues for 12 months or more. With high-volume surgeons, the large majority are continent or use only a small pad by one year. Pelvic floor physical therapy — ideally started before surgery — speeds recovery.
Erectile function: recovery depends on age, baseline function, and nerve-sparing status, and can take 6–24 months. PDE5 inhibitors (sildenafil, tadalafil), vacuum devices, and penile rehabilitation help.
Fertility: the surgery removes the prostate and seminal vesicles, so ejaculation no longer occurs. Sperm banking before surgery is an option if future fertility matters.
Final pathology report (about 1–2 weeks after surgery) is important — it can upgrade or downgrade the cancer and determines whether additional treatment is advised.
Radiation Therapy
Radiation is a proven curative alternative to surgery for localized disease, and is combined with ADT for many intermediate- and high-risk cancers. For many localized cancers, surgery and radiation give similar cancer control — the choice often turns on side-effect priorities, other health conditions, logistics, and personal preference.
Modern EBRT uses techniques such as IMRT (intensity-modulated) and VMAT, with image guidance, to shape the radiation dose tightly around the prostate while sparing the bladder and rectum. A traditional course runs about 4–8 weeks of daily weekday treatments. Shorter, “hypofractionated” schedules are well supported for many patients and reduce visits.
SBRT delivers very high, precise doses in a small number of sessions — often five or fewer. It is increasingly used for low- and favorable intermediate-risk disease, with mature outcomes. Its advantages include convenience and often lower financial toxicity due to fewer visits.
Low-dose-rate (LDR): permanent radioactive seeds placed in the prostate, usually in a single outpatient procedure. Standard for low-risk and selected intermediate-risk disease.
High-dose-rate (HDR): temporary catheters deliver a high dose over one or two sessions, then are removed. Often combined with EBRT for higher-risk disease.
For unfavorable intermediate- and high-risk disease, adding a brachytherapy “boost” to EBRT improves biochemical control compared with a standard external-beam boost, supported by randomized trials. The ASCENDE-RT trial’s 15-year results showed that overall survival was similar between the two approaches, but in the primary cause-of-death analysis the brachytherapy boost was associated with fewer prostate-cancer deaths.
The honest trade-off remains: better cancer control against a higher risk of long-term urinary and bowel side effects. The choice should be individualized.
ADT duration is matched to risk:
Favorable intermediate-risk: radiation alone is often appropriate; a genomic classifier can help decide whether short-term ADT adds enough benefit.
High- and very-high-risk: longer-course ADT (commonly 18–36 months) is standard.
Duration is individualized by risk, age, and other health conditions — long enough for the cancer benefit, not longer.
Rectal spacer (e.g., SpaceOAR): a biodegradable gel placed between the prostate and rectum, pushing the rectum out of the high-dose field. Reduces rectal side effects and improves bowel-related quality of life.
Fiducial markers: tiny gold seeds placed in the prostate to help target radiation precisely.
Proton therapy: available at select centers (including Huntsman Cancer Institute). It may reduce dose to surrounding tissue, but clear clinical superiority over modern IMRT for prostate cancer has not been demonstrated; modality should be individualized.
Urinary: frequency, urgency, and weak stream during and for some weeks after treatment, usually improving over time.
Bowel: loose stools, rectal urgency, occasionally minor bleeding; usually temporary, and reduced by spacers and modern technique.
Sexual: erectile dysfunction tends to develop gradually over 1–3 years after radiation, influenced by baseline function and ADT use.
Fatigue: common during the course, generally resolving afterward.
Comparing Treatment Options for Localized Disease
For low- and favorable-intermediate-risk disease, active surveillance, surgery, and radiation can all be reasonable. The right choice often depends on which trade-offs matter most to the individual.
What You May Prioritize
Surgery
Radiation
Active Surveillance
Avoiding urinary leakage
Leakage common early, usually improves over months
Less immediate leakage
Best preserves urinary function
Avoiding bowel effects
Bowel effects uncommon
Some bowel/rectal risk (reduced by spacer)
Best preserves bowel function
Preserving erections
Depends on nerve-sparing and age; often a drop early
Tends to decline more gradually over years
Best preserves sexual function
Having exact final pathology
Yes — whole prostate examined
Not obtained
Not applicable
Convenience / logistics
One operation, then recovery
Daily visits over weeks, or ~5 for SBRT
Periodic visits, ongoing monitoring
Avoiding treatment for now
Treatment now
Treatment now
Defers treatment, with option to treat later
A known bias worth naming. Studies consistently show that men who consult only a surgeon are far more likely to end up with surgery, and men who see only a radiation oncologist more likely to receive radiation. The remedy is simple: before choosing treatment for localized disease, see both a urologist and a radiation oncologist — ideally in a coordinated multidisciplinary clinic.
🔀 Decision Flowchart: After Prostate Cancer Diagnosis
flowchart TD
A([Biopsy Confirmed]) --> B{Low Risk - Gleason 6}
B -->|Yes| C([Active Surveillance])
B -->|No| D{Intermediate Risk}
D -->|Yes| E[Discuss Options]
E --> F([Surgery])
E --> G([Radiation + Short ADT])
D -->|No| H{High Risk}
H -->|Yes| I[Multimodal Treatment]
I --> J([Surgery + Possible RT])
I --> K([Radiation + Long ADT])
H -->|No| L{Metastatic}
L -->|Yes| M[Systemic Therapy]
M --> N([ADT + Next-Gen Hormonal])
Simplified overview — actual decisions involve many more factors. Discuss with your medical team.
Treatment Phases with Practical Checklists
Not every patient passes through every phase. Use the ones that apply to your situation.
Goal: confirm the exact risk group, complete staging, start molecular testing, and choose the path.
Confirm pathology and Grade Group; arrange second-opinion pathology review for borderline cases
Document the full PSA history; calculate PSA density if relevant
Obtain mpMRI; obtain PSMA PET (or CT + bone scan) for unfavorable-intermediate-risk and higher
Order germline testing if indicated; order somatic testing if metastatic
Consult urology AND radiation oncology; add medical oncology if high-risk or metastatic
Ask: “What is my exact NCCN risk group, and what are all guideline-concordant options for that group?”
Goal: choose and carry out local therapy, with full supportive care from the start.
If surgery:
Start pelvic floor physical therapy before surgery
Plan catheter care for 1–2 weeks; review recovery timeline
Review final pathology report at about 2 weeks; first PSA at 4–6 weeks (should be undetectable)
Begin penile rehabilitation roughly one month after surgery
If radiation:
Complete simulation and planning (~2–3 weeks)
Start ADT if indicated; confirm planned duration
Manage bowel, bladder, and skin symptoms; ask about a rectal spacer
Set the PSA monitoring schedule during and after treatment
Goal: start the backbone promptly and intensify without delay.
Start ADT promptly — do not wait for genomic results to begin the backbone
Within about two weeks, decide intensification (doublet or triplet) based on disease volume and fitness
Baseline labs; bone-health assessment (DEXA); cardiovascular risk review and choice of ADT agent
Order germline and somatic testing; ask about clinical trials
Consider radiation to the prostate for low-volume metastatic disease
Goal: re-profile the disease and sequence therapy by evidence and biomarkers.
Prostate cancer cells are fueled by androgens — male hormones, chiefly testosterone. ADT lowers testosterone to “castrate” levels (below 50 ng/dL), starving the cancer.
LHRH agonists (leuprolide, goserelin, triptorelin): given by injection every 1–6 months. They briefly raise testosterone (“flare”) before suppressing it. A short course of a first-generation antiandrogen (such as bicalutamide) is usually given for the first few weeks to prevent the flare from temporarily worsening symptoms.
LHRH antagonists (degarelix by injection; relugolix, an oral pill): suppress testosterone quickly without the initial flare.
Bilateral orchiectomy (surgical removal of the testicles): permanent, immediate, and least expensive. Rarely chosen today, but remains an option.
A central modern principle. For metastatic disease, ADT alone is no longer the standard of care for men fit enough for combination therapy. Adding an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide) and/or docetaxel chemotherapy extends survival — by years for many men. The conversation should not be “ADT or not?” It should be “ADT plus which intensification?”
ADT has been linked to a modest increase in cardiovascular risk. The HERO trial of relugolix (an oral LHRH antagonist) showed it suppressed testosterone rapidly without an initial flare and was associated with substantially fewer major cardiovascular events than leuprolide — about 2.9% versus 6.2% over the trial.
For a man with a history of heart attack, stroke, heart failure, or significant cardiovascular risk factors, it is worth specifically asking about relugolix as the ADT backbone. One trade-off: relugolix is a daily pill — missed doses can let testosterone rise again — whereas injected agents are given every one to six months.
Side Effect
Management
Hot flashes
Venlafaxine or gabapentin, lifestyle measures, layered clothing; acupuncture helps some men
Fatigue
Exercise — both resistance and aerobic — is the single most effective intervention; treat anemia, poor sleep, and depression
Loss of libido and erectile dysfunction
Counseling, PDE5 inhibitors, vacuum devices, injections; involve the partner
Bone density loss
Baseline DEXA scan; calcium and vitamin D; bone-protective agents when indicated
Cardiovascular and metabolic risk
Monitor blood pressure, lipids, and glucose; optimize diet and exercise; coordinate with primary care or cardiology
Muscle loss and weight gain
Resistance exercise and nutritional counseling
Mood changes and “brain fog”
Usually mild; discuss with the team; exercise and good sleep help
Exercise is genuine medicine here. Supervised resistance training and aerobic exercise are the best-proven interventions to counter ADT-related fatigue, muscle loss, bone loss, and metabolic change. Aim for roughly 150 minutes a week of moderate aerobic activity plus two or more resistance sessions, as tolerated and as your team advises.
If having children is a possibility — even a remote one — talk to the team about sperm banking before starting any systemic treatment. ADT works by suppressing testosterone, and that suppression also halts sperm production for as long as ADT continues. In men on long-term ADT, sperm production may not fully recover after stopping. The same applies to chemotherapy (docetaxel), which can temporarily reduce sperm count. Sperm banking is straightforward: a same-day appointment at a fertility clinic, typically one or two samples collected before the first ADT injection. Frozen sperm remains viable for decades. Even older men who feel certain they do not want more children sometimes find they appreciate having the option. Surgery (radical prostatectomy) removes the seminal vesicles and cuts the ejaculatory ducts, so after RP a man will have “dry orgasms” — no ejaculation of semen — but sperm can still be retrieved surgically from the testicles later if needed. Radiation to the prostate usually delivers very little scatter to the testicles with modern shielding, but some men may notice reduced ejaculate volume. Bottom line: ask the urologist or oncologist about fertility preservation before treatment starts. Most fertility specialists can see oncology patients quickly. This conversation takes five minutes and could matter greatly.
After surgery or radiation, PSA should fall to very low (ideally undetectable) levels. A subsequent rise is called biochemical recurrence (BCR) — and while the word “recurrence” sounds alarming, BCR is not the same as visible metastatic disease. In many men, PSA rises slowly for years before — or without ever — progressing to symptoms or to cancer that can be seen on a scan. What matters most at BCR is how fast the PSA is rising (the PSA doubling time) and what imaging shows. A very short doubling time (under six months) calls for prompt action; a slow doubling time (over 12 months) often warrants close monitoring rather than immediate treatment. The most useful new tool is the PSMA PET/CT scan, which can detect tiny amounts of cancer at PSA levels that were invisible to old-style bone scans and CT. If PSA rises, the team will likely order a PSMA-PET before deciding on next steps — it can determine whether the cancer is confined to the pelvis (where salvage radiation often cures), limited to a small number of spots that can be treated locally, or more widely spread (where systemic treatment is needed). BCR does not mean a cure has been lost. Many men live for decades after BCR. Having this conversation with the team early, before PSA climbs further, keeps the most options open.
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
“Metastatic hormone-sensitive” means the cancer has spread but still responds to testosterone suppression. The single most important principle: treatment must be intensified — ADT alone is not the standard for men fit enough for more.
“High-volume” disease generally means four or more bone metastases with at least one beyond the spine and pelvis, or any spread to organs such as the liver or lungs. “Low-volume” disease is everything below that threshold. Volume guides the intensity of treatment.
Trial / Regimen
What It Showed
CHAARTED — docetaxel + ADT
Adding docetaxel to ADT extended overall survival; benefit clearest in high-volume disease.
STAMPEDE — docetaxel or abiraterone + ADT
Both docetaxel and abiraterone added to standard care improved survival; a large platform trial that reshaped practice.
LATITUDE — abiraterone + prednisone + ADT
Improved overall survival in high-risk mHSPC.
ARCHES / ENZAMET — enzalutamide + ADT
Enzalutamide added to ADT improved progression-free and overall survival.
TITAN — apalutamide + ADT
Apalutamide added to ADT improved overall survival, across high- and low-volume disease.
ARANOTE — darolutamide + ADT (doublet)
Darolutamide added to ADT reduced the risk of progression or death. FDA-approved as a doublet for mHSPC in June 2025 (ARANOTE). Low drug-interaction profile, which can be an advantage for men taking several other medications.
Adding darolutamide to docetaxel + ADT improved survival; established triplet therapy for fit patients.
PEACE-1 — abiraterone + docetaxel + ADT (triplet)
Adding abiraterone to docetaxel + ADT improved outcomes, with an overall survival benefit in high-volume disease.
The current standard for mHSPC is ADT plus one of the following, chosen with the medical oncologist:
Doublet — ADT + an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide). Appropriate across volumes; often preferred for low-volume disease or men who cannot take chemotherapy.
Doublet — ADT + docetaxel chemotherapy. Often favored for fit, younger men with high-volume disease.
Triplet — ADT + docetaxel + an androgen receptor pathway inhibitor (per ARASENS or PEACE-1). The most intensive option, with the strongest evidence in fit men with high-volume disease.
One more option in low-volume mHSPC: radiation to the prostate itself (STAMPEDE program) improved survival for men with low-volume metastatic disease, and is often added to systemic therapy.
Do not delay. The window when the cancer is still hormone-sensitive is the single best opportunity to extend life. Start the ADT backbone promptly and decide on intensification within roughly two weeks — do not wait months, and do not delay for unproven alternatives.
The PSMAddition trial tested adding lutetium-177 PSMA radioligand therapy to standard ADT-plus-ARPI treatment in metastatic hormone-sensitive disease, and met its progression-free survival endpoint. This is the first phase 3 trial of radioligand therapy in hormone-sensitive disease. It is not yet an approved use, but it may expand the role of PSMA therapy earlier in the disease — a reasonable question to raise with a GU oncologist.
Castration-Resistant Disease
An important in-between stage: the PSA begins to rise even though testosterone is at castrate levels, but scans show no metastases. The key number is the PSA doubling time — a doubling time of 10 months or less marks higher risk and is the trigger for treatment.
Three phase 3 trials — SPARTAN (apalutamide), PROSPER (enzalutamide), and ARAMIS (darolutamide) — each showed that adding one of these agents to continued ADT delays metastases and improves overall survival. The standard approach is therefore apalutamide, enzalutamide, or darolutamide added to ADT.
“Oligometastatic” refers to a limited number of metastases — often one to three, sometimes up to five — frequently detected because sensitive PSMA PET imaging finds spots conventional scans would miss. Metastasis-directed therapy means treating each visible metastasis directly, usually with focused high-dose radiation (SBRT).
Randomized phase 2 trials support this approach: ORIOLE found that SBRT delayed progression, and STOMP found that metastasis-directed therapy delayed the need to start ADT. This is a genuinely growing area, but it is not a substitute for appropriate systemic therapy and should be discussed in a multidisciplinary setting.
When the cancer progresses despite castrate testosterone, it is called castration-resistant. mCRPC is generally not curable, but it is often controllable for a meaningful time, and the number of effective options has grown substantially.
Option
Key Points
ARPIs — abiraterone, enzalutamide
Standard if not already used; supported by COU-AA-302 and PREVAIL trials.
Chemotherapy — docetaxel, then cabazitaxel
A backbone for many patients; cabazitaxel is used after docetaxel.
PARP inhibitors — for HRR-mutated disease
For tumors with BRCA1/2 or other HRR mutations. Olaparib (PROfound) and rucaparib are options. Also combined with ARPIs in first-line: talazoparib + enzalutamide (TALAPRO-2), olaparib + abiraterone (PROpel), niraparib + abiraterone (MAGNITUDE). Benefit concentrates in HRR-mutated disease, especially BRCA1/2.
For PSMA-PET-positive disease. VISION trial showed improved survival after an ARPI and a taxane. FDA expanded approval to the setting after an ARPI but before chemotherapy, based on PSMAfore trial. Requires PSMA PET to confirm uptake.
Immunotherapy — pembrolizumab
For the small subset of MSI-high or mismatch-repair-deficient tumors; can produce durable responses. Not effective in unselected prostate cancer.
Radium-223
For symptomatic bone-predominant metastases without visceral spread; improves survival and reduces skeletal events.
Sipuleucel-T
A cellular immunotherapy for men with few or no symptoms; a modest survival benefit. Used less often now.
Bone-protective agents
Zoledronic acid or denosumab at cancer dosing reduce fractures and skeletal complications in the castration-resistant setting.
Genomic testing is essential here. Before deciding on a PARP inhibitor or immunotherapy, the tumor must be tested for HRR mutations (BRCA1/2) and MSI-high / mismatch-repair status. PSMA PET imaging is needed for lutetium-177 therapy eligibility.
Abiraterone is always given with low-dose prednisone (a steroid). It can cause high blood pressure, low potassium, and fluid retention, and can affect liver enzymes. Expect periodic blood-pressure checks, potassium, and liver-function blood tests. Report swelling, unusual muscle weakness, or new shortness of breath to the team.
Genomic & Molecular Testing: The Decision Tree
Modern prostate cancer care is increasingly guided by the tumor’s biology at the molecular level. There are three distinct kinds of testing — keeping them straight is genuinely useful.
Germline testing analyzes a blood or saliva sample for mutations the patient was born with. Who should be tested:
All men with metastatic prostate cancer
All men with high-risk or very-high-risk localized disease, or node-positive disease
Men with any risk group plus a strong family history of prostate, breast, ovarian, pancreatic, or colorectal cancer
Men with intraductal or cribriform features on biopsy
Men of Ashkenazi Jewish ancestry, or with a known family mutation, or diagnosed at an early age
Genes typically tested: BRCA1, BRCA2, ATM, CHEK2, PALB2 and other HRR genes; mismatch-repair / Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM); and HOXB13.
Why it matters: A BRCA1/2 or select HRR mutation can make the patient eligible for PARP inhibitors if the disease advances. An inherited mutation also means relatives may benefit from cascade testing and earlier screening. Roughly 1 in 8 men with metastatic prostate cancer carries an inherited DNA-repair mutation.
Somatic testing sequences the cancer cells’ DNA — mutations the tumor acquired. It uses tumor tissue or a blood-based “liquid biopsy” (ctDNA). Recommended for metastatic disease and considered for high-risk localized disease.
What it looks for:
HRR-gene mutations (BRCA1/2, ATM, CDK12, PALB2, CHEK2): open PARP inhibitor therapy in mCRPC. BRCA2 is the most predictive of benefit.
MSI-high / mismatch-repair deficiency (under ~5% of cases): opens immunotherapy with pembrolizumab.
High tumor mutational burden (TMB): may predict immunotherapy response.
Other alterations (PTEN, RB1, TP53 loss): associated with more aggressive disease; inform prognosis and trial matching.
A note on “variants of uncertain significance” (VUS): a VUS should not, on its own, drive treatment choices or family testing — a genetic counselor can interpret it in context.
Distinct from mutation testing, tissue-based genomic classifiers measure gene activity or analyze the biopsy image to estimate aggressiveness. Two are recognized in NCCN guidelines: the Decipher 22-gene classifier and ArteraAI Prostate, a multimodal AI test (FDA-authorized in 2025). Both carry a high NCCN evidence rating.
These tools are used across risk groups to inform shared decisions — supporting more intensive surveillance in low-risk disease, helping decide whether to add ADT to radiation in intermediate-risk disease, and weighing radiation after surgery with adverse pathology.
Finding
What It Can Unlock
Germline BRCA1/2 or other HRR mutation
Family cascade testing and earlier screening; PARP inhibitor eligibility if disease advances
Somatic HRR mutation (BRCA1/2, ATM, etc.)
PARP inhibitor therapy in mCRPC; possible platinum chemotherapy sensitivity
MSI-high / mismatch-repair deficient
Immunotherapy with pembrolizumab
PSMA-positive on PET imaging
Lutetium-177 PSMA radioligand therapy; more accurate staging
High genomic classifier score (Decipher / ArteraAI)
Supports more intensive surveillance, adding ADT to radiation, or adding radiation after surgery
Logistics. Order genomic testing through the cancer center’s genetics or precision-oncology team. Insurance usually covers indicated testing, but pre-authorization is often required — ask the clinic’s genomic navigator to start that paperwork early. Get all results in writing.
Where to Get Treated & the Second-Opinion Strategy
One of the most important choices a family makes is where care is delivered. The gap between a strong multidisciplinary academic program and a general community setting can be meaningful.
Pathology expertise. Expert second-opinion review can change the risk group and the whole treatment plan.
Surgical and radiation volume. Higher volumes correlate with better outcomes.
Multidisciplinary tumor boards. When specialists review a case together, plans are more complete and evidence-aligned.
Clinical trial and theranostics access. NCI-designated centers offer trials and advanced therapies not available everywhere.
For patients in Utah and the surrounding region, Huntsman Cancer Institute at the University of Utah in Salt Lake City is the only NCI-designated Comprehensive Cancer Center serving the Mountain West. For prostate cancer specifically, Huntsman runs a dedicated multidisciplinary GU Cancers program with:
Coordinated multidisciplinary care with tumor boards
Advanced radiation and surgery (robotic prostatectomy, IMRT, SBRT, brachytherapy, proton therapy)
A national leader in theranostics — PSMA PET imaging and lutetium-177 PSMA therapy
Integrated genomic testing and counseling
A large clinical trials portfolio, including the largest early-phase program in the Mountain West
Supportive services: nurse navigation, financial counseling, exercise oncology, integrative medicine
Appointments: 801-587-7000 · 2000 Circle of Hope Drive, Salt Lake City, UT 84112
A second opinion is most useful when it has a specific job — not as generic reassurance. When it is especially worthwhile:
Any intermediate- or high-risk diagnosis, before committing to definitive treatment
Metastatic disease at diagnosis
Unclear or borderline pathology or imaging
Rare molecular features, or a desire to access a specific clinical trial
A difficult surgery-versus-radiation decision
How to do it efficiently: Pick one strong national center rather than shopping many opinions. Send biopsy slides, imaging discs, PSA history, and genomic results. Ask about remote / virtual second opinions — pathology and imaging review can usually be done without travel.
If the Cancer Progresses or Recurs
A rising PSA after treatment, or progression on therapy, is frightening — but it is also a well-mapped situation with clear next steps. The key is to locate the problem accurately before acting.
After radical prostatectomy, PSA should fall to undetectable. A confirmed PSA of 0.2 ng/mL or higher is biochemical recurrence.
Salvage radiation to the prostate bed is most effective when started early, while PSA is still low (generally under 0.5 ng/mL).
PSA persistence: if PSA never becomes undetectable after surgery, that warrants prompt evaluation rather than watching.
ADT with salvage radiation: the EMBARK trial studied high-risk biochemical recurrence — enzalutamide plus leuprolide improved 5-year metastasis-free survival and confirmed an overall-survival benefit at final analysis. EMBARK led to FDA approval of enzalutamide for high-risk biochemical recurrence.
EMBARK does not replace early salvage radiation. For a man whose recurrence appears local and who is a candidate for curative-intent salvage radiation, that radiation — most effective at a low PSA — remains the priority. EMBARK-style systemic therapy is discussed in context; it does not automatically substitute for early salvage radiation.
After radiation, biochemical recurrence is generally defined as a PSA rise of 2 ng/mL or more above the lowest level reached (the nadir).
PSMA PET is the preferred imaging to locate the recurrence — local, regional nodes, or distant.
Salvage options for local recurrence include salvage prostatectomy (technically difficult — best at high-volume centers), and in selected cases salvage cryotherapy, HIFU, or brachytherapy. These carry higher complication rates than primary treatment.
Systemic therapy if metastatic disease is found or strongly suspected.
Confirm castrate testosterone status
Re-image with PSMA PET to map disease and confirm PSMA expression
Re-biopsy a metastatic site, or use a liquid biopsy, to detect new actionable mutations
Reassess HRR, BRCA, and MSI status
Sequence systemic therapy by prior exposure and biomarkers, and screen for clinical trials
If recurrence is found as oligometastatic disease (a limited number of spots), metastasis-directed radiation may be considered alongside systemic therapy.
Palliative care is specialized care focused on symptom control, quality of life, and aligning treatment with the patient’s goals. It is delivered alongside active, life-prolonging treatment — not only at the end of life. Early integration of palliative care improves quality of life and, in several studies, outcomes. Asking for a palliative care referral early is a sign of good planning, not surrender.
class="content-section" data-stage="progression">
Clinical Trials
Every standard therapy in prostate cancer today began as a clinical trial. Trials should be treated as a treatment option to consider at every stage, not a backup for when standard care fails.
Access to promising therapies before they are widely available
Closer monitoring through scheduled visits, imaging, and labs
Contribution to knowledge that helps future patients
An important reassurance — with a caveat. Ethically designed cancer trials should not withhold proven treatment — most compare standard care plus a promising addition against standard care. But trial designs vary. Ask exactly what each arm includes, whether any standard treatment is delayed or omitted, and what happens if the cancer progresses.
Next-generation PSMA-targeted agents — including PSMA radioligand therapy combined with PARP inhibitors, and alpha-particle PSMA therapy (actinium-225)
Androgen receptor degraders — drugs designed to destroy the receptor protein entirely, which may overcome resistance to current hormonal agents
Bispecific antibodies — a newer class of immunotherapy targeting proteins such as STEAP1 or KLK2, showing unusually strong early responses in heavily pretreated disease
Other immunotherapy approaches — checkpoint combinations and cellular therapies
Metastasis-directed therapy — focused radiation to oligometastatic disease
Bipolar androgen therapy — cycling testosterone between high and low levels, studied for quality-of-life benefits and re-sensitizing tumors
De-escalation strategies — testing whether some men with favorable features can safely receive less intensive treatment
These are some of the major trials that have shaped or are shaping prostate cancer treatment. Knowing the trial name helps when discussing options with your team.
Trial
NCT Number
What It Studies
CHAARTED
NCT00309985
Adding docetaxel chemo to ADT for metastatic hormone-sensitive disease
LATITUDE
NCT01715285
Adding abiraterone to ADT for high-risk metastatic disease
TITAN
NCT02489318
Adding apalutamide to ADT for metastatic hormone-sensitive disease
ARASENS
NCT02799602
Triplet therapy: darolutamide + docetaxel + ADT
PEACE-1
NCT01957436
Triplet therapy: abiraterone + docetaxel + ADT
VISION
NCT03511664
Lutetium-177 PSMA therapy for advanced castration-resistant disease
PROfound
NCT02987543
Olaparib (PARP inhibitor) for BRCA/HRR-mutated castration-resistant disease
EMBARK
NCT02319837
Enzalutamide for high-risk non-metastatic biochemical recurrence
PSMAfore
NCT04689828
Lutetium-177 PSMA therapy earlier in treatment (before chemo)
PSMAddition
NCT04720157
Adding lutetium-177 PSMA to standard treatment for newly diagnosed metastatic disease
Search any NCT number at clinicaltrials.gov for full details, eligibility, and locations.
ClinicalTrials.gov — search “prostate cancer” plus the situation (e.g., “high-risk localized,” “mHSPC,” “BRCA,” “PSMA”); filter by recruiting status and location.
NCI Cancer Information Service — 1-800-4-CANCER, and the NCI trials search at trials.cancer.gov.
The cancer center’s clinical trials office — at Huntsman, ask the GU navigator about open trials at every visit.
Patient advocacy organizations — Prostate Cancer Foundation, ZERO Prostate Cancer, and others offer trial navigation help.
What phase is this trial, and what is its goal?
What is the standard-of-care arm, and what is the experimental arm? Will I receive at least standard treatment?
What have earlier results shown?
What extra visits, tests, or risks are involved? Are travel and lodging costs covered?
Can I withdraw at any time and return to standard treatment?
What happens if the treatment stops working or I cannot tolerate it?
class="content-section" data-stage="progression">
Directory of Major Prostate Cancer Centers
Phone numbers and program details change. Confirm them when you call. Many centers offer remote second-opinion review of pathology, imaging, and genomics — ask specifically about that option if travel is difficult.
How to choose: academic center vs. community vs. VA.
Academic / NCI-designated center — best for complex or high-risk disease, second-opinion pathology, clinical trial access, and multidisciplinary tumor board review. Consider when the case is borderline, when a rare histology or mutation is found, or when standard options have been exhausted.
High-quality community program — appropriate for straightforward low- or favorable-intermediate-risk disease when the treating team is experienced and follows NCCN guidelines. Advantages: proximity, convenience, continuity with primary care.
VA medical center — eligible veterans should explore VA care, which provides comprehensive prostate cancer treatment including genomic testing, PSMA imaging, and access to national VA clinical trials at no out-of-pocket cost. The VA can coordinate with academic centers when specialized care is needed.
When in doubt, start with a consultation at the nearest NCI-designated center or VA GU oncology program. A single visit for a second opinion does not require transferring all care.
Huntsman Cancer Institute (University of Utah)
2000 Circle of Hope Dr, Salt Lake City, UT 84112 · 801-585-0303
NCI-designated Comprehensive Cancer Center; multidisciplinary GU program; PSMA-PET imaging; robotic surgery; brachytherapy; proton therapy; theranostics leader; largest Phase 1 program in the region
University of Utah Health
Salt Lake City, UT · 801-581-2121
Academic medical center affiliated with Huntsman; urology and radiation oncology departments
Intermountain Health
Multiple locations, Utah · 801-442-2000
Prostate cancer care including robotic prostatectomy, IMRT/SBRT, ADT management; precision genomics program
University of Colorado Cancer Center (Anschutz)
Aurora, CO · 720-848-0300
NCI-designated Comprehensive Cancer Center; GU oncology with expertise in mCRPC sequencing and theranostics
Center
Location / Contact
Particular Strengths
Johns Hopkins — Brady Urological Institute
Baltimore, MD · 410-955-6100
Pioneering prostate cancer research; active-surveillance expertise; pathology review
Memorial Sloan Kettering
New York, NY · 800-525-2225
High-volume GU oncology; PSMA imaging and radioligand therapy; extensive trials
MD Anderson Cancer Center
Houston, TX · 877-632-6789
Large multidisciplinary GU program; brachytherapy expertise; broad trial portfolio
Mayo Clinic
Rochester, MN · 507-538-3270
Integrated care model; proton therapy; advanced imaging and genomic testing
UCSF — Helen Diller
San Francisco, CA · 415-353-7177
Active-surveillance and molecular-imaging expertise; translational research
Dana-Farber / Brigham
Boston, MA · 617-632-3000
Precision oncology; PARP inhibitor and immunotherapy research
Advanced prostate cancer trials and precision medicine
George E. Wahlen VA Medical Center — Salt Lake City, UT · 801-582-1565. Affiliated with University of Utah and Huntsman Cancer Institute. GU oncology with access to VA national clinical trial network.
VA National Oncology Program — All VA medical centers provide prostate cancer screening, diagnosis, and treatment. The PACT Act (2022) expanded eligibility for veterans with toxic exposure-related cancers, including those linked to Agent Orange. VA Precision Oncology Program offers genomic testing (somatic and germline) for eligible veterans.
VA Clinical Trials — The VA Cooperative Studies Program runs multi-center prostate cancer trials across the VA system. Ask the VA oncology team about open trials at every visit.
For veterans: VA prostate cancer care has no copay for service-connected conditions. Even non-service-connected veterans may be eligible for VA oncology care based on income and disability status. Contact the local VA enrollment coordinator or call 1-877-222-8387 (VA Health Benefits Hotline).
Center
Location / Contact
Particular Strengths
Princess Margaret Cancer Centre
Toronto, ON · +1 416-946-2000
One of the largest cancer centers globally; leading GU program; brachytherapy expertise; PSMA theranostics; global trial participation
Sunnybrook Health Sciences Centre — Odette Cancer Centre
Toronto, ON · +1 416-480-6100
High-volume radiation oncology; active-surveillance research; robotic surgery
McGill University Health Centre
Montreal, QC · +1 514-934-1934
GU oncology program; clinical trials; uro-oncology multidisciplinary care
BC Cancer — Vancouver Centre
Vancouver, BC · +1 604-877-6000
Provincial cancer agency; early adopter of PSMA theranostics; radiation expertise
Center
Location / Contact
Particular Strengths
The Royal Marsden NHS Foundation Trust
London, UK · +44 20 7352 8171
World-leading prostate cancer research; STAMPEDE trial leadership; PARP inhibitor and theranostics expertise
University Hospital Heidelberg
Heidelberg, Germany · +49 6221 56-0
Pioneer in PSMA imaging and theranostics; global referral center for PSMA-based diagnosis and treatment
Institut Gustave Roussy
Villejuif, France · +33 1 42 11 42 11
Europe’s largest cancer center; PEACE-1 trial leadership; comprehensive GU program
Peter MacCallum Cancer Centre
Melbourne, Australia · +61 3 8559 5000
Australia’s dedicated public cancer hospital; TheraP trial site; PSMA theranostics leader
National Cancer Center Hospital
Tokyo, Japan · +81 3 3542 2511
Japan’s leading oncology center; proton therapy; GU clinical trials in the Asia-Pacific region
International Perspectives
Several important advances in prostate cancer care originated outside the United States and reached clinical use abroad before US regulatory approval. Awareness of these developments can be valuable, particularly for patients exploring treatment options or seeking care internationally.
PSMA-targeted theranostics — the pairing of PSMA PET imaging tracers (gallium-68 and fluorine-18 PSMA) with the therapeutic radiopharmaceutical lutetium-177-PSMA-617 (now marketed as Pluvicto) — were developed and used in clinical practice at Heidelberg University Hospital in Germany and at leading Australian centers years before US FDA approval. The pivotal VISION trial, which led to FDA approval of lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, confirmed what German and Australian clinicians had observed through earlier compassionate-use and single-center experience.
Germany and Australia remain global leaders in PSMA research, clinical application, and next-generation PSMA agent development. Patients exploring PSMA-based therapies — particularly those not yet approved in the US or those seeking earlier access — may find that these countries offer broader clinical availability and deeper institutional expertise.
For US-based patients: PSMA PET imaging and lutetium-177-PSMA-617 are now FDA-approved and available at major US academic centers. However, patients interested in next-generation PSMA agents (such as actinium-225 alpha-particle PSMA therapy) may find additional options through clinical trials or compassionate access programs at German and Australian institutions.
The PATCH trial (Prostate Adenocarcinoma TransCutaneous Hormones), led by investigators in the United Kingdom, studied transdermal estradiol patches as an alternative to standard LHRH agonist injections for androgen deprivation therapy. The rationale: estradiol delivered through the skin suppresses testosterone effectively while avoiding the first-pass liver metabolism that made older oral estrogen therapies (such as diethylstilbestrol) unacceptably cardiotoxic.
Potential advantages over LHRH agonists:
Cardiovascular profile: Transdermal estradiol avoids the prothrombotic changes associated with oral estrogens and may carry a lower cardiovascular risk than LHRH agonists, though definitive long-term data are still maturing.
Bone density: Estradiol preserves bone mineral density rather than accelerating bone loss, potentially reducing fracture risk — a significant concern with long-term LHRH agonist use.
Hot flashes: Estradiol substantially reduces or eliminates hot flashes, one of the most bothersome ADT side effects.
Transdermal estradiol for prostate cancer ADT is not standard practice in the United States and is not included in current NCCN guidelines as a primary ADT option. It is, however, available in some countries and may be offered at centers familiar with the PATCH trial data. Patients interested in this approach should discuss it with their medical oncologist or urologist, with an understanding that it remains outside mainstream US practice.
This is not a DIY option. Hormone manipulation in prostate cancer requires expert supervision. Do not attempt to source or self-administer estradiol patches for cancer treatment without oncology guidance. The dosing, monitoring, and contraindication profile differ from standard hormone-replacement uses.
Supportive Care & Quality of Life
Side effects are not afterthoughts — they are central to good care. Most are manageable, and many respond best to interventions started early.
Before treatment: pelvic floor physical therapy (“prehabilitation”) — learning Kegel exercises correctly, ideally with a specialized therapist.
After surgery: expect some leakage at first; continue exercises; improvement continues for 12+ months. If significant leakage persists past a year, a male sling or artificial urinary sphincter can be very effective.
After radiation: urinary frequency and urgency are common and usually improve within months.
A randomized controlled trial published in JAMA compared electroacupuncture to sham acupuncture for urinary incontinence following radical prostatectomy.
Design: Randomized, sham-controlled trial in men with persistent urinary incontinence after radical prostatectomy.
Continence recovery:43.6% of men in the electroacupuncture group achieved continence vs. 21.8% in the sham group — a clinically meaningful difference (p<0.001).
What this means: Electroacupuncture roughly doubled the likelihood of continence recovery compared with sham treatment. For men struggling with persistent leakage after surgery, this is a low-risk intervention worth discussing with the care team, particularly alongside pelvic floor exercises.
Limitations: A single trial, though well-designed with sham control. Results should be confirmed in additional studies across different surgical populations. Electroacupuncture requires access to a trained practitioner.
Source: Liu Z, et al. Electroacupuncture for urinary incontinence after radical prostatectomy. JAMA.
Both surgery and radiation can significantly affect sexual function; baseline age and erectile function are the strongest predictors of recovery. A structured penile rehabilitation program, started early, gives the best chance.
PDE5 inhibitors (sildenafil, tadalafil) — most effective when nerves are intact; best as part of a rehabilitation program
Vacuum erection devices — a non-drug option useful early
Penile prosthesis — a surgical option for ED that does not respond to other measures; high satisfaction rates
Psychosexual counseling — addresses intimacy, body image, and partner communication; valuable and underused
Radiation can cause bowel side effects — loose stools, urgency, occasional rectal bleeding — mostly temporary and reduced by rectal spacers and modern technique. Persistent late symptoms (radiation proctitis) are treatable; rectal bleeding years after radiation should be evaluated by a gastroenterologist.
ADT accelerates bone loss, and prostate cancer commonly spreads to bone. The bone-health plan — DEXA scans, calcium and vitamin D, weight-bearing exercise, and bone-protective agents when indicated — should begin when starting long-term ADT. Painful bone lesions can be treated with targeted palliative radiation; radium-223 is an option for symptomatic bone-predominant mCRPC.
ADT can raise blood pressure, cholesterol, blood sugar, and weight. Men on ADT should have regular monitoring and coordinate with primary care or cardiology. Exercise, smoking cessation, and a heart-healthy diet are important — cardiovascular disease, not prostate cancer, is the leading cause of death for many men with localized disease.
Fatigue is among the most common and distressing symptoms. Exercise is the single most effective remedy. Energy conservation, treating contributing causes (anemia, depression, poor sleep), and mind-body approaches all help.
Anxiety, depression, and fear of recurrence are common after a prostate cancer diagnosis — and ADT’s hormonal shifts can amplify mood changes. This is treatable. Distress screening, counseling, support groups, and — when appropriate — medication or psychiatry referral are all part of good care. Watch for signs of depression and raise them with the team.
Supporting the Patient & Family
Every treatment decision involves trade-offs. There is rarely one “right” answer — there is the answer that best fits a particular man’s biology, values, and circumstances. A useful question to return to: “What matters most to you over the next 5 to 10 years?” When sexual and urinary function are discussed, the partner should be in the room.
Listen without rushing to “fix” everything
Attend appointments; take notes; help track the binder and the calendar
Respect the patient’s autonomy — the treatment decision is his to make
Encourage healthy habits without pressuring or policing
Watch for depression and raise concerns gently with the team
Coordinate practical help — meals, rides, updates — using a tool like CaringBridge or a shared calendar
Take care of your own health; rotate caregiving among more than one person if possible
Honest hope is not blind optimism. It means doing the work the situation requires while genuinely pursuing every reasonable treatment option. For low-risk localized disease, the outlook is excellent. For intermediate- and high-risk localized disease, cure is genuinely possible for a large share of men. For metastatic disease, modern intensification, genomic-guided therapy, and PSMA approaches have extended survival meaningfully — some men live many years, even decades, with good quality of life. The patient is not a statistic, and the choices made along the way move the odds.
Regardless of stage or prognosis, having an up-to-date will, a durable power of attorney for healthcare and finances, and an advance directive is an act of love for one’s family — not a prediction. If the patient is employed, look into Family and Medical Leave Act protections early.
Ranked Priorities for the Next Three Months
If only one page of this guide gets read, let it be this one.
Confirm an accurate risk group. Get the exact Grade Group, full PSA history, and stage, with second-opinion pathology review. Everything downstream depends on this.
Complete staging. Obtain mpMRI, and PSMA PET (or CT + bone scan) for unfavorable-intermediate-risk and higher disease.
See the right specialists before deciding. Consult both a urologist and a radiation oncologist for localized disease; add a medical oncologist for high-risk or metastatic disease.
Start genomic testing if indicated. Germline testing for metastatic, high/very-high-risk, or node-positive disease; somatic testing for metastatic disease.
Match treatment intensity to risk. Low-risk: structured active surveillance. High-risk localized: multimodal therapy. Metastatic: start ADT plus intensification within weeks.
Choose an experienced center and team. Surgeon and hospital volume, tumor boards, and trial access all move outcomes.
Build the supportive-care plan now. Pelvic floor PT, baseline DEXA scan if starting ADT, cardiovascular review, and an exercise program.
Pre-plan the recurrence playbook. Know in advance which imaging and molecular tests would be used, and what salvage options exist.
The bottom line. Get the right risk group, get the right team, and make decisions based on guidelines and the patient’s own values. Early, coordinated, evidence-based action gives the best chance of an excellent outcome.
Questions to Ask Each Doctor
Bring these to the matching specialist. Mark the ones most relevant to your situation.
What is my Grade Group, number of positive cores, percent cancer per core, and PSA density?
What is my exact NCCN risk group, and what are all guideline-concordant options?
Has my pathology been reviewed by a genitourinary specialist pathologist?
Am I a candidate for active surveillance? If borderline, why?
Should I have a PSMA PET scan to stage my cancer?
Should I have a genomic classifier test, or germline genetic testing?
How do my age and other health conditions affect my options?
Am I a candidate for nerve-sparing surgery — one side or both?
How many radical prostatectomies do you perform per year? How many at this center?
What are your positive-margin, 12-month continence, and potency-recovery rates for patients like me?
Will you perform a pelvic lymph node dissection, and with what template?
What is your plan if the final pathology shows adverse features?
What continence and sexual rehabilitation do you recommend, and when does it start?
What technique and dose/fractionation do you recommend, and why?
Would a brachytherapy boost improve my chance of cure, and what are the trade-offs?
Will I receive ADT with radiation, and for how long?
Do you use a rectal spacer? Am I a candidate?
What are the expected acute and late side effects — urinary, bowel, sexual?
How will we monitor my PSA, and what is the plan if it rises?
Is my disease hormone-sensitive or castration-resistant? High-volume or low-volume?
Do I meet criteria for intensification — a doublet or triplet — and which do you recommend?
Have germline and somatic testing been done? What would results change?
Am I PSMA-PET-positive, and a current or future candidate for lutetium-177 therapy?
What is the goal of this treatment — cure, control, or symptom relief?
What are the next-line options if this treatment stops working?
Which ADT agent is best for me given my heart history?
What clinical trials are open for my situation?
Where exactly is the recurrence — local, regional nodes, or distant?
Should I have a PSMA PET scan now?
Should the tumor be re-biopsied (or a liquid biopsy done) for new mutations?
What clinical trials might fit me now?
What are my realistic goals now — and are we still aligned on them?
Financial & Practical Resources
Cancer treatment is expensive, and “financial toxicity” is real. Navigating it proactively prevents care delays.
Item
Coverage Note
Germline genetic testing
Often $0–$250 out of pocket when NCCN criteria are met
Somatic tumor profiling
Frequently covered for advanced disease; pre-authorization usually required
PSMA PET scan
Coverage has improved substantially for staging and recurrence
Novel hormonal agents
High list prices; out-of-pocket cost varies, especially on Medicare Part D
PARP inhibitors
High monthly cost; usually covered for indicated mutation; pre-authorization required
Lutetium-177 PSMA therapy
High per-dose cost; Medicare covers; commercial coverage varies
Second opinion
Often covered or encouraged by insurance; remote review avoids travel cost
Use the cancer center’s financial navigators. Most NCI-designated centers have counselors who help with insurance appeals, copay assistance, and manufacturer programs.
Ask about manufacturer patient assistance programs for high-cost drugs.
Understand Medicare Part D. Out-of-pocket spending on covered Part D prescription drugs is now capped annually (about $2,100 in 2026). Infused or radiopharmaceutical therapies may be billed under Part B with different cost-sharing.
Know workplace protections — the Family and Medical Leave Act and the Americans with Disabilities Act.
Consider nonprofit assistance: Patient Advocate Foundation (800-532-5274), CancerCare (800-813-4673), HealthWell Foundation (800-675-8416), Good Days (877-968-7233).
Clinical trial costs: by law, routine standard-of-care costs are billed to insurance; the experimental drug is provided by the sponsor.
Treatment choice can reduce cost: when options are equivalent, a shorter radiation course (SBRT) can mean fewer visits.
NCCN Guidelines for Patients (Prostate Cancer) — nccn.org/patients
Prostate Cancer Foundation — pcf.org
ZERO Prostate Cancer — zerocancer.org
American Cancer Society — cancer.org; 1-800-227-2345
AnCan Foundation (virtual support groups) — ancan.org
Family Caregiver Alliance — caregiver.org; 800-445-8106
ClinicalTrials.gov; NCI Cancer Information Service — 1-800-4-CANCER
Supplements: What Helps, What Does Not, and What to Avoid
Men with prostate cancer are heavily marketed supplements. Some genuinely support health during treatment; several are disproven; a few are dangerous when combined with cancer drugs.
Selenium and high-dose vitamin E: The large SELECT trial (over 35,000 men) found selenium does not prevent prostate cancer and vitamin E slightly increased risk. Stop these if taken for prostate cancer.
Pomegranate extract: A definitive randomized trial found it no better than placebo. The fruit is fine, but the supplement has no proven cancer benefit.
High-dose zinc (above ~25 mg/day): linked to more aggressive disease in long-term data. Keep zinc low.
Exercise — the best-supported intervention. ~150 minutes/week of aerobic activity plus 2+ resistance sessions.
Calcium and vitamin D at guideline doses (~1,000–1,200 mg calcium and 800–2,000 IU vitamin D daily) to support bone health during ADT.
Melatonin (~3–5 mg at night) for ADT-related sleep disturbance; not known to interact with prostate cancer drugs.
A heart-healthy (Mediterranean-style) diet supports overall and cardiovascular health.
Sulforaphane is a naturally occurring compound concentrated in broccoli sprouts and other cruciferous vegetables. It activates Nrf2 detoxification pathways and has shown anti-cancer effects in laboratory models of prostate cancer.
Clinical evidence: A double-blind randomized controlled trial in men on active surveillance found that stabilized broccoli sprout extract (sulforaphane) slowed PSA doubling time compared with placebo. PSA rises were significantly attenuated in the sulforaphane group.
Mechanism: Sulforaphane induces phase II detoxification enzymes through the Nrf2-Keap1 pathway, promotes apoptosis in prostate cancer cell lines, and modulates androgen receptor signaling in preclinical studies.
What this means: The evidence is early but biologically plausible and from a well-designed trial. Sulforaphane may be a reasonable discussion for men on active surveillance seeking evidence-based dietary strategies. It is not a substitute for standard treatment.
Practical notes: Bioavailability varies widely between preparations. Myrosinase-active or stabilized formulations are better absorbed. Dietary intake through broccoli sprouts (30–60 g/day) is an alternative. Generally well tolerated; gastrointestinal upset is the most common side effect.
Limitations: Small trial size. Long-term oncologic outcomes (cancer progression, need for treatment) are not yet established from randomized data. Should be disclosed to the oncology team.
Supplement
Concern
What to Do
St. John’s Wort
Strongly speeds breakdown of ARPIs, taxane chemotherapy, and PARP inhibitors — can cause treatment failure
Do not combine
Curcumin with piperine / BioPerine
Piperine alters drug metabolism; can affect ARPI and chemotherapy levels
Avoid piperine-containing formulations during treatment
CBD / cannabis oil
Can alter metabolism of ARPIs and chemotherapy
Disclose to oncology team; do not use as cancer treatment
Grapefruit / Seville orange
Can raise levels of abiraterone and some other drugs
Avoid during abiraterone treatment
Saw palmetto
Can lower PSA and confound monitoring
Stop during treatment — PSA is the key tracking tool
High-dose antioxidants during chemo
May theoretically blunt chemotherapy’s effect
Do not take on infusion days; discuss timing with the team
The single most important supplement rule. Tell the oncology team about every supplement, vitamin, and herbal product being taken — including “natural” ones. They are not automatically safe, and a brief mention can prevent a serious interaction.
Honest Uncertainties in Prostate Cancer Care
Prostate cancer is among the most-researched cancers, yet real uncertainties remain. These are not reasons for fear — they are reasons to ask the team what is known and what is still being learned.
Optimal ADT duration with radiation for intermediate-risk disease — how long is truly necessary for an individual man remains debated.
How to treat very small-volume disease found only on PSMA PET — whether to treat as true metastatic disease or localized disease with micrometastases is still being studied.
Optimal sequencing in mCRPC — the best order of ARPIs, chemotherapy, PARP inhibitors, and PSMA radioligand therapy is not fully defined.
De-escalation — whether some men with favorable genomics can safely receive less intensive treatment is the subject of ongoing trials.
The role of focal therapy — focal therapy treats only the cancerous area of the prostate rather than the whole gland, aiming to reduce side effects. The main modalities include HIFU (high-intensity focused ultrasound), cryotherapy (freezing), TULSA-PRO (MRI-guided transurethral ultrasound ablation), and laser ablation. Whether these will prove non-inferior to whole-gland treatment in long-term cancer control awaits definitive randomized trials; discuss with your urologist if you are interested.
Immunotherapy beyond the MSI-high subset — combinations and novel approaches are under investigation.
The strength of lifestyle interventions — exercise and diet are supported by observational data, but randomized trials with cancer-specific endpoints are limited.
Individual tolerance — a regimen easy for one man may be intolerable for another, requiring personalized adjustment.
The most important thing about these uncertainties. They do not mean care is guesswork. They mean prostate cancer medicine is a living, fast-moving field. The treatment available today is substantially better than what existed even five years ago. Engage with the uncertainty by asking questions — a team that can say clearly what is known and what is not is a team worth trusting.
PSMA stands for prostate-specific membrane antigen — a protein expressed on the surface of prostate cancer cells. A PSMA PET/CT scan injects a tiny amount of radioactive tracer that binds to PSMA, then uses a scanner to find cancer cells anywhere in the body with much higher sensitivity than traditional CT scans or bone scans. What this means in plain terms: PSMA-PET can detect prostate cancer spread at PSA levels as low as 0.2 ng/mL, a threshold at which a conventional CT scan would be completely normal. For men who have had surgery or radiation and whose PSA is rising, PSMA-PET often determines whether cancer has returned locally (in the pelvis, where salvage radiation can still aim for cure) or has spread to distant lymph nodes or bone (where systemic treatment is the focus). PSMA-PET is also used before treatment in men with high-risk disease to check for hidden spread before committing to local therapy. For treatment of advanced disease with the drug lutetium PSMA (Pluvicto), a PSMA-PET scan is required to confirm the cancer “lights up” before the drug will work. Two FDA-approved PSMA tracers are available in the US: gallium-68 PSMA-11 and piflufolastat (Pylarify). Both work well; availability depends on the imaging center. If PSMA-PET is recommended, ask the team why it is being ordered, what result would change management, and what it would mean if the scan is negative or positive. The answers clarify the decision path ahead.
Failed & De-Adopted Therapies
Knowing what has been tried and did not work is important. It protects against outdated advice and helps families evaluate claims critically. The following therapies were once used or studied for prostate cancer but have been abandoned, withdrawn, or significantly de-emphasized based on negative evidence.
DE-ADOPTED
DES was one of the earliest forms of androgen deprivation, used from the 1940s through the 1980s. It effectively suppressed testosterone but caused unacceptably high rates of cardiovascular complications — heart attacks, strokes, and thromboembolic events — due to first-pass hepatic metabolism. LHRH agonists and antagonists replaced DES as the standard of care. The concept of estrogen-based ADT has been revisited via transdermal estradiol (the PATCH trial), which avoids the first-pass liver effect, but oral DES itself is no longer used.
FAILED
The SELECT trial (Selenium and Vitamin E Cancer Prevention Trial) enrolled over 35,000 men to test whether selenium, vitamin E, or both could prevent prostate cancer. The trial was stopped early: neither supplement reduced prostate cancer risk, and high-dose vitamin E (400 IU/day) was associated with a statistically significant 17% increase in prostate cancer diagnoses. Extended follow-up confirmed these findings. These supplements should not be taken for prostate cancer prevention.
DE-ADOPTED
Sipuleucel-T (Provenge) is an autologous cellular immunotherapy that was FDA-approved in 2010 for asymptomatic or minimally symptomatic mCRPC, based on a modest overall survival benefit of about 4 months in the IMPACT trial. However, it showed no PSA decline or radiographic response, making it difficult for patients and physicians to assess whether it was working. With the arrival of more effective agents — enzalutamide, abiraterone, lutetium-177 PSMA-617, and PARP inhibitors — sipuleucel-T is now rarely used in practice. It remains technically available but has been functionally displaced.
FAILED
Early uncontrolled studies suggested pomegranate juice or extract could slow PSA rise in men with biochemical recurrence. A definitive, well-powered randomized controlled trial found pomegranate extract was no better than placebo. Eating pomegranates is fine as part of a healthy diet, but the supplement has no proven benefit for prostate cancer and should not be used as a treatment strategy.
FAILED
Ipilimumab (Yervoy), a CTLA-4 checkpoint inhibitor that transformed outcomes in melanoma, was tested in two large phase 3 trials in metastatic castration-resistant prostate cancer (CA184-043 and CA184-095). Neither trial met its primary overall survival endpoint. Prostate cancer’s low mutational burden and immunosuppressive microenvironment limit checkpoint inhibitor efficacy in unselected patients. Immunotherapy with pembrolizumab remains effective for the small MSI-high/dMMR subset, but broad checkpoint blockade has not succeeded in prostate cancer.
FAILED
Bevacizumab, an anti-VEGF antibody effective in several other cancers, was tested in combination with docetaxel in the phase 3 CALGB 90401 trial for metastatic castration-resistant prostate cancer. The addition of bevacizumab did not improve overall survival and increased toxicity, including more treatment-related deaths. Anti-angiogenic strategies have not proven effective in prostate cancer.
DE-ADOPTED
Whole-gland cryotherapy (freezing the entire prostate) was used as a primary treatment alternative to surgery or radiation. However, it carries high rates of erectile dysfunction (often near-total), urinary side effects, and lacks the long-term cancer-control data supporting surgery and radiation. NCCN guidelines do not recommend whole-gland cryotherapy as a standard primary treatment. It may still have a limited role in salvage settings (after radiation failure) at experienced centers, and focal cryotherapy is being studied in clinical trials.
Why this list matters. If someone recommends a therapy on this list — or anything not in current guidelines — ask for the specific clinical trial evidence. Prostate cancer has a long history of ideas that looked promising in the laboratory but failed in rigorous human testing. The treatments that work today survived that testing; these did not.
Fertility Preservation, Partner Safety & Prostate Cancer
Prostate cancer affects men. The pregnancy-related considerations for prostate cancer patients focus on sperm banking before treatment, the effects of treatment on fertility, and safety for pregnant partners.
Sperm banking before treatment
If you are of reproductive age and planning to have children in the future, sperm banking is strongly recommended before starting any prostate cancer treatment — especially before:
Radiation therapy (external beam or brachytherapy): can affect sperm production by radiation scatter to nearby structures, though the main radiation field is targeted to the prostate.
Hormone therapy (ADT — androgen deprivation therapy with LHRH agonists/antagonists or anti-androgens): significantly reduces testosterone, which stops sperm production. Sperm production often — but not always — returns after stopping ADT.
Chemotherapy (docetaxel, cabazitaxel): toxic to sperm-producing cells.
Surgery (radical prostatectomy): does not directly harm sperm production, but retrograde ejaculation (semen going backward into the bladder) is common, affecting natural conception. Sperm retrieval can still be used for assisted reproduction.
Partner safety during brachytherapy (seed implants)
If you receive radioactive seed implants (low-dose-rate brachytherapy), a small amount of radiation can be emitted from the seeds. Precautions include:
For the first 2-4 months after implant: avoid sustained close contact with pregnant women and young children (follow your radiation oncologist's specific instructions).
Your partner should not have prolonged contact with the seed implant area for the first few weeks.
Sexual activity is generally safe after the healing period; your radiation oncologist will advise on timing.
When can you try to conceive after treatment?
After radiation therapy: most oncologists recommend waiting at least 6-12 months for sperm quality to recover from radiation scatter effects. Sperm banking before treatment is therefore important.
After hormone therapy (ADT): testosterone and sperm production typically begin to recover 6-18 months after stopping ADT, though recovery is not guaranteed (particularly after long-duration ADT). Fertility assessment before attempting conception is recommended.
After radical prostatectomy: while sperm production may be intact, retrograde ejaculation is common. Assisted reproductive techniques (intrauterine insemination using sperm retrieved from urine) may be needed.
Talk to your oncologist before starting treatment about sperm banking if you are interested in future fatherhood. This is a time-sensitive conversation — ideally, sperm should be banked before treatment begins.
Glossary
Active surveillance
Structured monitoring of low-risk cancer with periodic PSA, exams, MRI, and biopsies, deferring treatment unless progression occurs.
ADT
Androgen deprivation therapy — treatment that lowers testosterone to castrate levels.
Changes and additions since this guide was first published. Newest updates appear first.
26 May 2026NewEmerging research added — Electroacupuncture for post-prostatectomy incontinence: sham-controlled RCT showing continence recovery 43.6% vs. 21.8% (JAMA). Sulforaphane (broccoli sprout extract): double-blind RCT showing attenuated PSA rise in men on active surveillance. Landmark Trials table updated. Go to section →
22 May 2026NewGuide published — Comprehensive prostate cancer research guide covering risk stratification, active surveillance, surgery, radiation, ADT & intensification, advanced disease, genomic testing, clinical trials, supportive care, and practical resources. Based on NCCN v5.2026, AUA/ASTRO/SUO, and EAU guidelines. Go to top →
22 May 2026TrialEMBARK final survival data included — Enzalutamide plus leuprolide confirmed overall-survival benefit in high-risk biochemical recurrence, leading to FDA approval. Go to section →
22 May 2026TrialARANOTE doublet approval — Darolutamide + ADT FDA-approved as a doublet for mHSPC in June 2025 (ARANOTE). Go to section →
22 May 2026TrialPSMAfore / VISION / PSMAddition data — Lutetium-177 PSMA-617 expanded approval (pre-chemotherapy mCRPC) and PSMAddition results in hormone-sensitive disease. Go to section →
22 May 2026UpdatedNCCN 2026 risk group change — “Very-low-risk” category eliminated and merged into “low risk.” Go to section →
22 May 2026NewEarly detection & screening section — PSA screening guidance, family cascade testing, and screening recommendations for higher-risk men. Go to section →
LHRH agonist testosterone flare: leuprolide (Lupron) and goserelin (Zoladex) initially cause a brief surge in testosterone before suppression begins (first 1-2 weeks); in men with extensive bone metastases or disease near the spinal cord, this surge can worsen bone pain, worsen urinary obstruction, or in rare cases cause spinal cord compression
Anti-androgen flare protection is mandatory for men with high-volume metastatic disease: bicalutamide or another anti-androgen must be started 1-2 weeks before and continued through the first 2-4 weeks of LHRH agonist therapy to block the testosterone flare; LHRH antagonists (degarelix/Firmagon, relugolix/Orgovyx) do not cause flare and are preferred in men with high spinal disease burden
Spinal cord compression warning signs in metastatic prostate cancer — emergency: new back pain that is worse at night or when lying down; leg weakness or numbness; difficulty walking; loss of bladder or bowel control — call 911 or go to ER immediately; this is a spinal oncological emergency requiring urgent imaging and often surgical decompression or radiation
Androgen deprivation therapy (ADT) long-term effects: bone loss requires mandatory DEXA scan and bone protection (calcium 1200 mg/day + vitamin D 800-1000 IU/day; bisphosphonate or denosumab if osteoporosis); cardiovascular risk increases (metabolic syndrome; diabetes monitoring; cardiac evaluation); weight gain; hot flushes; cognitive/mood effects — regular monitoring appointments are essential during ADT
Abiraterone (Zytiga) — always taken with prednisone: mineralocorticoid excess causes hypertension, hypokalemia (low potassium), and fluid retention — BP and electrolyte monitoring required; never stop prednisone abruptly (adrenal suppression); take abiraterone on an empty stomach (food increases absorption 10x — can cause serious toxicity); take abiraterone acetate (Zytiga) on empty stomach OR abiraterone (Yonsa) with food (formulation-specific)
Enzalutamide (Xtandi) — seizure risk: enzalutamide increases seizure risk; avoid activities requiring alertness (driving, operating machinery) until response is known; report any seizure, loss of consciousness, or new neurological symptoms; contraindicated in patients with a history of seizure disorder or structural brain lesions predisposing to seizures
Radium-223 (Xofigo): myelosuppression — CBC monitoring; thrombocytopenia (report unusual bruising); report fever or signs of infection; do not use concurrently with abiraterone (increased fracture/death in early trial data)